CD274 and non-small cell lung carcinoma: PD-1/PD-L1 antibodies have demonstrated impressive anti-tumor responses by releasing the PD-1/PD-L1-mediated control of the immune system, and this activity has therefore become a highly promising treatment strategy for NSCLC in recent years (10).